Q3 2025 Apyx Medical Corp Earnings Call Transcript
Key Points
- Apyx Medical Corp (APYX) reported a 12% increase in total revenue for the third quarter of 2025, reaching $12.9 million compared to $11.5 million in the same period last year.
- The company's surgical aesthetics segment saw a 19% increase in revenue, driven by the successful launch of the Aon body contouring system.
- Apyx Medical Corp (APYX) achieved a significant reduction in operating expenses, which decreased to $9.1 million from $10.6 million in the prior year period.
- The company reported a substantial decrease in net loss attributable to stockholders, which was $2 million for the third quarter of 2025, compared to $4.7 million in the prior year period.
- Apyx Medical Corp (APYX) increased its full-year 2025 revenue guidance, reflecting strong demand and successful commercial launch of the Aon system.
- OEM revenue decreased by 18% to $1.8 million for the third quarter of 2025, down from $2.2 million in the same period last year.
- International revenue decreased by 4% year over year to $3.5 million.
- The company is still in the early stages of the Aon system launch, and while initial feedback is positive, long-term market acceptance remains to be fully realized.
- Cash and cash equivalents decreased to $25.1 million as of September 30, 2025, from $31.7 million at the end of 2024.
- The company faces uncertainties related to tariffs and trade policies, which could impact future financial performance.
Good morning, ladies and gentlemen, and welcome to the Apyx Medical third quarter 2025 earnings conference call. (Operator Instructions) This call is being recorded on Thursday, November 6, 2025. I would now like to turn the conference over to Jeremy Feffer, LifeSci advisor. Please go ahead, sir.
Thank you and welcome everyone to our third quarter 2025 earnings call. Representing the company on the call are Charlie Goodwin, Chief Executive Officer, and Matt Hill, Chief Financial Officer of Apyx. Before we begin, I would like to remind everyone that our remarks and responses to your questions today may contain forward-looking statements that are based on the current expectations of management and involve inherent risks
and uncertainties that could cause actual results to differ materially from those indicated, including, without limitation, those identified in the risk factors section of our most recent annual report on Form 10k, our most recent 10Q filing, and the company's other filings
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
